marzan,
I believe the news we are waiting on is going to take the stock price up fairly quickly to a range between $11-$24 based on initial buyout value low ball estimates that does not take into consideration the platform tech this represents. Eventually the price will settle into an upward forward P/E angle this year based on validated production ramp capability at the estimated approval date. I believe we’ll know more about that angle when we hear from Charles Rivers Labs and get an expected approval date or get a partnership or joint venture (Linda will not sell the value of Direct or improved L for pennies on the dollar so do not expect buyout this year). The proof is in the pudding and Charles Rivers Labs has the experience and firepower to get things done and that ability is not connected to NWBO (a clear disconnect in valuation) in the eyes of investors right now even though Charles Rivers Labs is obviously prepping their manufacturing capacity for something big. Once we have updated capacity numbers and the ability to project capacity ramp, timing on eventual reimbursement rate for various types of cancer treated and some idea of when Direct will come on board based on early results from trials then the logarithmic rise in valuation will take place. That could also begin just on speculation about the time that investors in general will realize what is happening and that this is going to happen. This year is the pivotal year for all of this to begin to come into fruition and by the end of this year the spec value plus initial income will take the price to a minimum of $24 with a buyout value @ minimum $50 ( that won’t be accepted) by the end of 2022. Best wishes.
Market Data 
Markets 
AI
